10-Q: Paysign Reports Q1 2024 Results: Revenue Growth Driven by Pharma and Plasma Sectors

Paysign's first quarter of 2024 saw a significant increase in revenue, driven by growth in both the pharmaceutical and plasma industries, resulting in a net income of $309,096.

Summary

• Paysign, Inc. reported its financial results for the first quarter of 2024, showing a total revenue of $13.19 million, a 30% increase compared to $10.14 million in the same period last year.
• The company's revenue growth was primarily driven by a 10.8% increase in plasma industry revenue to $10.37 million and a substantial 305.2% increase in pharma industry revenue to $2.39 million.
• Other revenue also saw a significant increase of 123.8% to $433,396.
• The company's gross profit increased by 37.5% to $6.94 million, with a gross margin of 52.6%, up from 49.8% in the prior year.
• Operating expenses totaled $7.20 million, an increase of 24.3% year-over-year, primarily due to increased compensation, technology costs, and depreciation and amortization.
• Paysign reported a net income of $309,096 for the quarter, a significant improvement from a net loss of $160,130 in the first quarter of 2023.
• The company's adjusted EBITDA was $1.69 million, compared to $720,463 in the same period last year.
• Gross dollar volume loaded on cards was $426 million, compared to $379 million in the same period last year.
• The company's cash and restricted cash totaled $115.32 million at the end of the quarter.

Sentiment

Score: 8

Explanation: The document presents a strong positive outlook with significant revenue growth, improved profitability, and a healthy cash position. While there are some risks and increased operating expenses, the overall tone is optimistic and indicates a positive trajectory for the company.

Positives

• Paysign experienced significant revenue growth across all sectors, particularly in the pharma industry.
• The company's gross profit and gross margin improved year-over-year.
• Paysign moved from a net loss to a net income, indicating improved profitability.
• Adjusted EBITDA more than doubled compared to the same period last year.
• The company's cash position remains strong with over $115 million in cash and restricted cash.

Negatives

• Operating expenses increased by 24.3% year-over-year, driven by higher compensation, technology costs, and depreciation and amortization.
• The company recorded a loss from operations of $258,352, although this was an improvement from the previous year's loss.

Risks

• The company is subject to credit risk due to its cash holdings with one financial institution, although a deposit swapping program has been initiated to mitigate this risk.
• One pharma program customer represents 22% of the company's accounts receivable balance, indicating a concentration of credit risk.
• The company is involved in ongoing legal proceedings, including securities class action and stockholder derivative actions, which could have an adverse impact on the business.
• The company's future performance is subject to various risks and uncertainties, including those related to market conditions, competition, and regulatory changes.

Future Outlook

The company plans to continue investing in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance. Paysign also evaluates raising capital to diversify into new market verticals, but believes it can support existing business and expand into new markets using internally generated funds if new capital is not raised.

Management Comments

• Management believes that the company's available cash on hand, along with its forecast for revenues and cash flows, will be sufficient to sustain operations for the next twenty-four months.
• Management reviews a number of metrics to help monitor the performance of and identify trends affecting the business.
• Management considers certain non-GAAP measures to be useful to management and investors evaluating the company's operating performance.

Industry Context

The prepaid card market in the U.S. has experienced significant growth, and Paysign is positioned to capitalize on this trend with its diverse product offerings and integrated payment platform. The company's focus on corporate incentive and expense prepaid card products aligns with market demand for streamlined payment solutions.

Comparison to Industry Standards

• Paysign's revenue growth of 30% year-over-year is strong compared to the broader payment processing industry, which has seen growth rates in the high single to low double digits.
• The 305.2% growth in pharma revenue is particularly notable, suggesting Paysign is gaining significant traction in this market segment.
• Companies like Wex Inc. and FleetCor Technologies, Inc. also operate in the payment solutions space, but Paysign's focus on prepaid cards and specific verticals like plasma and pharma differentiates it.
• Paysign's gross margin of 52.6% is competitive with other payment processors, but its operating expenses are higher, indicating room for improvement in efficiency.
• The company's move to profitability is a positive sign, as many smaller payment processors struggle to achieve consistent profitability.

Legal Proceedings

• The company is involved in ongoing legal proceedings, including securities class action and stockholder derivative actions.
• A settlement of $3,750,000 was reached in the securities class action, funded entirely by the company's directors-and-officers insurance policy.
• The company is a nominal defendant in four stockholder derivative actions, which are currently stayed or in the early stages of litigation.

Stakeholder Impact

• Shareholders will likely view the improved financial results positively.
• Employees may benefit from the company's growth and continued investment in technology and operations.
• Customers will benefit from the company's continued investment in its platform and services.
• Suppliers and creditors will likely see the company as a stable and reliable partner.

Next Steps

• The company plans to continue investing in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance.
• The company will continue to monitor the health and soundness of its bank relationships.
• The company will continue to evaluate raising capital to enable diversification into new market verticals.

Key Dates

Keywords

prepaid cards, payment processing, pharmaceutical, plasma, financial results, revenue growth, EBITDA, patient affordability, corporate incentives, digital banking